{"product_id":"understanding-thyroid-cancer-imaging-a-patients-guide-to-ct-and-mri-scans","title":"Understanding Thyroid Cancer Imaging: A Patient's Guide to CT and MRI Scans","description":"\u003cp\u003eThyroid cancer is increasingly discovered on CT and MRI scans, often as an unexpected finding. This patient-friendly guide explains how radiologists use CT and MRI to evaluate thyroid nodules, detect cancer spread to lymph nodes, plan surgery for invasive disease, and monitor for recurrence after treatment — covering all the key statistics and guidelines from the original 2013 medical review.\u003c\/p\u003e\n\n\u003ch1\u003eUnderstanding Thyroid Cancer Imaging: A Patient's Guide to CT and MRI Scans\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#introduction\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#types\"\u003eTypes of Thyroid Cancer and Risk Factors\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#imaging-protocol\"\u003eHow CT and MRI Are Performed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#incidental-nodules\"\u003eIncidental Thyroid Nodules: Unexpected Findings\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#nodal-metastases\"\u003eEvaluating Lymph Node Spread\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#invasion\"\u003ePreoperative Imaging for Invasive Disease\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recurrence\"\u003eEvaluating for Recurrence After Treatment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIncidental thyroid nodules are found in up to 1 in 6 neck CT scans, but only 0-9% are malignant.\u003c\/li\u003e\n\u003cli\u003eIn a Japanese study, no deaths occurred over 10 years in patients with non-aggressive small thyroid cancers who received no treatment.\u003c\/li\u003e\n\u003cli\u003eIodinated CT contrast can delay radioiodine treatment by 2-6 months, so MRI is a useful alternative.\u003c\/li\u003e\n\u003cli\u003eUp to 61% of lymph node metastases are smaller than 10 mm, so size alone is not a reliable predictor.\u003c\/li\u003e\n\u003cli\u003eA negative whole-body iodine scan occurs in 50-80% of patients with recurrent or persistent thyroid cancer.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"introduction\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eIf you've been told a thyroid abnormality was found on a CT or MRI scan, you're not alone. While ultrasound is the standard first test for a lump you can feel (a palpable thyroid nodule) or a known thyroid cancer, thyroid problems are frequently discovered first on CT and MRI scans done for entirely different reasons. This review article, published in \u003cem\u003eCancer Imaging\u003c\/em\u003e in 2013, explains how radiologists approach four common situations:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003eFinding an unexpected (incidental) thyroid nodule\u003c\/li\u003e\n  \u003cli\u003eEvaluating whether thyroid cancer has spread to lymph nodes\u003c\/li\u003e\n  \u003cli\u003ePre-surgical imaging when cancer appears to be invading nearby structures\u003c\/li\u003e\n  \u003cli\u003eChecking for cancer recurrence after treatment\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors — radiologists from Duke University, the University of Pittsburgh, Yale School of Medicine, the University of Melbourne, and the University of California San Francisco — emphasize that understanding how thyroid cancer behaves is essential for interpreting imaging correctly. This article translates their findings for patients and families navigating a thyroid cancer diagnosis.\u003c\/p\u003e\n\n\u003ch2 id=\"types\"\u003eTypes of Thyroid Cancer and Risk Factors\u003c\/h2\u003e\n\n\u003cp\u003eThyroid cancer is far more common than it used to be. The incidence is estimated at \u003cstrong\u003e37,000 new cases per year in the United States\u003c\/strong\u003e, and this number has \u003cstrong\u003emore than doubled over the last 30 years\u003c\/strong\u003e. Much of this increase is attributed to the discovery of incidental nodules on imaging rather than new environmental causes.\u003c\/p\u003e\n\n\u003cp\u003eThere are four main types of thyroid cancer, and their behavior varies dramatically:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePapillary thyroid carcinoma (88% of cases):\u003c\/strong\u003e The most common type, generally slow-growing and highly treatable.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFollicular thyroid carcinoma (8% of cases):\u003c\/strong\u003e Includes the Hurthle cell variant.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedullary thyroid carcinoma (1% of cases):\u003c\/strong\u003e Arises from neuroendocrine C cells that produce calcitonin.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnaplastic thyroid carcinoma (1% of cases):\u003c\/strong\u003e An aggressive, undifferentiated tumor that typically occurs in older adults.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOther primary cancers of the thyroid — such as squamous cell carcinoma, sarcoma, and lymphoma — are extremely rare, together accounting for \u003cstrong\u003eless than 1%\u003c\/strong\u003e of cases.\u003c\/p\u003e\n\n\u003cp\u003ePapillary and follicular carcinomas are grouped together as \u003cstrong\u003edifferentiated thyroid carcinomas (DTC)\u003c\/strong\u003e because they retain many features of normal thyroid tissue. Both have excellent prognoses, with \u003cstrong\u003e10-year survival rates greater than 95% for papillary and 85% for follicular carcinoma\u003c\/strong\u003e. Medullary thyroid carcinoma also has a favorable outlook, with a \u003cstrong\u003e75% survival rate at 10 years\u003c\/strong\u003e. In stark contrast, anaplastic carcinoma has a devastating \u003cstrong\u003e5-year survival rate of only 7%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eSmall papillary cancers are particularly noteworthy for their indolent (slow-moving) behavior. Epidemiological studies show that despite increased diagnosis of small thyroid cancers, survival rates have not improved — suggesting many of these cancers would never have caused harm. A Japanese study showed \u003cstrong\u003eno deaths over 10 years\u003c\/strong\u003e in patients with non-aggressive small thyroid carcinomas who received no treatment at all.\u003c\/p\u003e\n\n\u003cp\u003eRisk factors differ by cancer type. Papillary carcinoma is associated with ionizing radiation exposure, especially:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eChildhood head and neck radiation therapy\u003c\/li\u003e\n  \u003cli\u003eTotal body irradiation for bone marrow transplantation\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFamily history matters for both differentiated and medullary types. About \u003cstrong\u003eone-quarter of medullary thyroid carcinoma cases\u003c\/strong\u003e are linked to familial medullary thyroid carcinoma (FMTC), caused by inherited mutations in the \u003cstrong\u003eRET proto-oncogene\u003c\/strong\u003e. When FMTC occurs with tumors of other endocrine glands, it's called \u003cstrong\u003emultiple endocrine neoplasia (MEN)\u003c\/strong\u003e. Other familial syndromes associated with MTC include Cowden syndrome, familial polyposis, Carney complex, and Werner syndrome. In developing countries, follicular and anaplastic carcinomas have been linked to diets low in iodine.\u003c\/p\u003e\n\n\u003ch2 id=\"imaging-protocol\"\u003eHow CT and MRI Are Performed\u003c\/h2\u003e\n\n\u003cp\u003eIf you have known thyroid cancer, your doctors think carefully before ordering a contrast CT scan. This is because \u003cstrong\u003ethe free iodide load in contrast material interferes with iodine uptake in the thyroid for at least 6 to 8 weeks\u003c\/strong\u003e. For patients with differentiated thyroid cancer, this can delay diagnostic thyroid scans and radioiodine ablation therapy for \u003cstrong\u003e2 to 6 months\u003c\/strong\u003e, depending on the institution's policies. MRI contrast (gadolinium) does not interfere with iodine uptake, making MRI a valuable alternative in many cases.\u003c\/p\u003e\n\n\u003cp\u003eThe imaging protocols used at the authors' institutions are standardized:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCT:\u003c\/strong\u003e Multidetector imaging from the skull base to the tracheal bifurcation (the point where the windpipe splits), with or without contrast. Images are reconstructed in 2-mm slices in three planes: axial (top to bottom), coronal (front to back), and sagittal (side to side).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI:\u003c\/strong\u003e Similar coverage from skull base to tracheal bifurcation, including axial and coronal T1-weighted images, fat-suppressed T2-weighted images, and post-contrast axial and coronal T1-weighted images.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCommunication between the radiologist and referring clinician is essential before scanning — particularly to determine whether contrast is safe and appropriate for each patient's situation.\u003c\/p\u003e\n\n\u003ch2 id=\"incidental-nodules\"\u003eIncidental Thyroid Nodules: Unexpected Findings\u003c\/h2\u003e\n\n\u003cp\u003eWith the increased use of CT and MRI, \u003cstrong\u003eincidental thyroid nodules (ITNs)\u003c\/strong\u003e — sometimes called \"thyroid incidentalomas\" — have become a growing challenge. These are nodules found on scans performed for unrelated reasons. They are common, appearing in \u003cstrong\u003eup to 1 in 6 CT studies of the neck\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe dilemma for radiologists is real. In the absence of obvious local invasion or a hot spot on FDG-PET (fluorodeoxyglucose positron emission tomography), there are no CT or routine MRI features that reliably identify which nodules are malignant. Some studies have shown value in adding \u003cstrong\u003ediffusion-weighted imaging\u003c\/strong\u003e to neck MRI because benign nodules have a higher \"apparent diffusion coefficient\" value, but ultrasound remains the preferred test for further evaluation.\u003c\/p\u003e\n\n\u003cp\u003eThere are strong arguments \u003cem\u003eagainst\u003c\/em\u003e automatically working up every small incidental nodule with ultrasound:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe malignancy rate in incidental nodules is low, ranging from \u003cstrong\u003e0% to 9%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eThe prognosis for malignancy is excellent — many patients die \u003cem\u003ewith\u003c\/em\u003e their thyroid cancer, not \u003cem\u003efrom\u003c\/em\u003e it\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eYet radiologists worry about missing cancer. Many struggle with balancing cost-effectiveness against the fear of overlooking a potential tumor.\u003c\/p\u003e\n\n\u003cp\u003eBecause no official guidelines existed for reporting ITNs on CT and MRI, some authors suggested borrowing from ultrasound criteria and using a \u003cstrong\u003esize cut-off of 10 mm or 15 mm\u003c\/strong\u003e to decide which nodules need further testing. The most common method is a 10-mm cut-off — but this approach has a major drawback: up to \u003cstrong\u003e78% of incidentally detected nodules on CT\u003c\/strong\u003e would meet that threshold and require ultrasound, creating enormous numbers of unnecessary follow-up tests.\u003c\/p\u003e\n\n\u003cp\u003eDr. Hoang and colleagues proposed a better strategy — a \u003cstrong\u003e3-tiered risk categorization system\u003c\/strong\u003e based on nodule size \u003cem\u003ecombined with\u003c\/em\u003e features of advanced disease and patient age. Here's how it works:\u003c\/p\u003e\n\n\u003ctable border=\"1\" cellpadding=\"8\" cellspacing=\"0\"\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCategory\u003c\/th\u003e\n    \u003cth\u003eCharacteristics\u003c\/th\u003e\n    \u003cth\u003eRecommended Action\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\n\u003cstrong\u003eRisk Category 1:\u003c\/strong\u003e Highly suspicious for malignancy\u003c\/td\u003e\n    \u003ctd\u003ePET-avid thyroid nodule; associated lymphadenopathy (enlarged lymph nodes); extrathyroid spread with or without vocal cord palsy on the side of the nodule; lung metastases\u003c\/td\u003e\n    \u003ctd\u003eRecommend fine-needle aspiration biopsy\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\n\u003cstrong\u003eRisk Category 2:\u003c\/strong\u003e Indeterminate with risk factors\u003c\/td\u003e\n    \u003ctd\u003eHigh-risk history (see below); female age ≥20 years or male age ≤35 years; female age 20–35 years (young age alone may prompt consideration of ultrasound)\u003c\/td\u003e\n    \u003ctd\u003eRecommend ultrasound for further characterization\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\n\u003cstrong\u003eRisk Category 3:\u003c\/strong\u003e Indeterminate without risk factors\u003c\/td\u003e\n    \u003ctd\u003eNodule ≥1.5 cm or substantial interval growth; nodule \u0026lt;1.5 cm\u003c\/td\u003e\n    \u003ctd\u003eDescribe in the imaging impression; describe in the body of the report only\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-risk history\u003c\/strong\u003e includes: thyroid cancer in one or more first-degree relatives; history of external beam radiation as a child; exposure to ionizing radiation in childhood or adolescence; previous removal of one thyroid lobe (hemithyroidectomy) with discovery of thyroid cancer; MEN2\/FMTC-associated RET proto-oncogene mutation; or calcitonin level above 100 pg\/ml.\u003c\/p\u003e\n\n\u003cp\u003eThis system was tested in a study of \u003cstrong\u003e133 CT-detected incidental nodules\u003c\/strong\u003e at a single institution, using the National Cancer Institute's SEER database for comparison. The results were striking: compared with the old 10-mm size cut-off, the 3-tiered system using a \u003cstrong\u003e15-mm nodule size threshold\u003c\/strong\u003e identified \u003cstrong\u003ealmost half the number of nodules for workup\u003c\/strong\u003e while capturing the \u003cstrong\u003esame proportion of cancers\u003c\/strong\u003e — with no difference in the high-mortality cancers missed.\u003c\/p\u003e\n\n\u003ch2 id=\"nodal-metastases\"\u003eEvaluating Lymph Node Spread\u003c\/h2\u003e\n\n\u003cp\u003ePapillary carcinoma and medullary thyroid carcinoma are the types most likely to spread to lymph nodes. Nodal metastases are uncommon in follicular carcinoma. Sometimes, an enlarged lymph node is the \u003cem\u003efirst\u003c\/em\u003e sign of thyroid cancer — patients may have no visible thyroid abnormality at all. In this situation, any thyroid nodule seen on CT or MRI should be considered suspicious and evaluated further with ultrasound.\u003c\/p\u003e\n\n\u003cp\u003eIt's also important to know that some thyroid primaries may be \u003cstrong\u003ecompletely invisible on CT and MRI\u003c\/strong\u003e because they are small, diffuse, or multifocal (scattered in multiple areas of the gland). One illustrative case involved a 58-year-old man who presented with large cystic neck masses; his thyroid looked entirely normal on CT and even on ultrasound, yet surgery revealed \u003cstrong\u003emultifocal papillary carcinomas ranging from 0.1 cm to 1.4 cm\u003c\/strong\u003e in the isthmus and both lobes.\u003c\/p\u003e\n\n\u003cp\u003eFindings that suggest a neck mass originated from the thyroid include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCystic components\u003c\/strong\u003e (fluid-filled areas)\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eCalcifications\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntense enhancement\u003c\/strong\u003e after contrast\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProteinaceous or hemorrhagic content\u003c\/strong\u003e, appearing hyperdense on CT and bright (hyperintense) on T1-weighted MRI\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA critical warning from the authors: \u003cstrong\u003ecystic neck masses in young adults should not be dismissed as congenital cysts\u003c\/strong\u003e. They should be considered squamous cell carcinoma or thyroid carcinoma until proven otherwise. In one case, a 19-year-old woman had a cyst that looked simple and harmless on CT but was actually a level IV nodal metastasis from a 1-cm papillary carcinoma in her right thyroid lobe.\u003c\/p\u003e\n\n\u003ch3\u003eWhere Does Thyroid Cancer Spread?\u003c\/h3\u003e\n\n\u003cp\u003eThyroid nodal metastases commonly occur in the \u003cstrong\u003ecentral compartment (level VI)\u003c\/strong\u003e and \u003cstrong\u003elateral nodal groups (levels II–IV)\u003c\/strong\u003e. The \u003cstrong\u003eDelphian node\u003c\/strong\u003e (also called the prelaryngeal lymph node) is the highest lymph node in the central compartment. Involvement of this node in papillary thyroid cancer is a powerful predictor: patients with a Delphian node metastasis are \u003cstrong\u003enine times more likely to have lateral nodal involvement\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eOther sites that should not be neglected include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLower paratracheal nodes\u003c\/strong\u003e in the superior mediastinum (level VII)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRetropharyngeal nodes\u003c\/strong\u003e (behind the throat)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRetroesophageal groups\u003c\/strong\u003e (behind the esophagus)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOne case highlighted how subtle retropharyngeal nodes can be: a 52-year-old woman with papillary carcinoma had a metastatic right retropharyngeal node that was nearly invisible on standard CT windowing — only noticeable when the radiologist narrowed the window width to improve contrast.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eAJCC\/UICC TNM staging system\u003c\/strong\u003e classifies nodal stage by location:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eN1a:\u003c\/strong\u003e Level VI nodal disease (including pretracheal, paratracheal, and Delphian nodes)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eN1b:\u003c\/strong\u003e Unilateral or bilateral lateral cervical nodes, or superior mediastinal nodes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSuperior mediastinal involvement may prevent curative surgery, so CT or MRI may be ordered when predictors of mediastinal disease exist — such as lateral nodes or a primary tumor larger than 1.5 cm.\u003c\/p\u003e\n\n\u003cp\u003eA crucial point for radiologists: \u003cstrong\u003eabnormal nodal morphology (shape, internal characteristics) is a better predictor of metastatic disease than size alone\u003c\/strong\u003e, because up to \u003cstrong\u003e61% of nodal metastases are smaller than 10 mm\u003c\/strong\u003e — below the traditional size threshold for concern. Additionally, \u003cstrong\u003eskip metastases\u003c\/strong\u003e (discontinuous nodal spread that bypasses the central compartment) occur in up to \u003cstrong\u003e21% of medullary thyroid carcinoma cases\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"invasion\"\u003ePreoperative Imaging for Invasive Disease\u003c\/h2\u003e\n\n\u003cp\u003eFor most thyroid cancers — with the exception of most anaplastic carcinoma cases — treatment involves \u003cstrong\u003etotal or near-total thyroidectomy\u003c\/strong\u003e, \u003cstrong\u003ecentral nodal resection\u003c\/strong\u003e, and possibly \u003cstrong\u003eradioiodine ablation\u003c\/strong\u003e. Small tumors under 10 mm may be treated with lobectomy alone (removing just one lobe), but if the small tumors are multifocal, patients still need total thyroidectomy and radioiodine ablation.\u003c\/p\u003e\n\n\u003cp\u003eHere's an important limitation: \u003cstrong\u003eCT and MRI cannot reliably diagnose multifocal disease or determine the histology (cell type) of thyroid cancer\u003c\/strong\u003e. That's why preoperative evaluation starts with ultrasound to detect multifocal disease and lymphadenopathy. CT and MRI are added when local invasion is suspected.\u003c\/p\u003e\n\n\u003cp\u003eWhy does invasion matter so much? Locally invasive cancer may require:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore extensive surgery\u003c\/strong\u003e, such as laryngectomy (removal of the voice box)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdditional surgical specialists\u003c\/strong\u003e, such as thoracic or reconstructive plastic surgeons\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eA decision not to operate\u003c\/strong\u003e if the cancer is too extensive\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLocal invasion is also a key component of the AJCC\/UICC tumor (T) staging system. The system focuses on four groups of structures:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe \u003cstrong\u003eairway and nerves centrally\u003c\/strong\u003e (trachea, esophagus, larynx, and recurrent laryngeal nerve)\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003ecarotid arteries laterally\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003eprevertebral space posteriorly\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003emediastinum inferiorly\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable border=\"1\" cellpadding=\"8\" cellspacing=\"0\"\u003e\n  \u003ctr\u003e\n    \u003cth\u003eT stage\u003c\/th\u003e\n    \u003cth\u003eSize\u003c\/th\u003e\n    \u003cth\u003ePresence of Invasion\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eT1\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e≤2 cm\u003c\/td\u003e\n    \u003ctd\u003eNo extracapsular invasion\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eT2\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u0026gt;2 cm, ≤4 cm\u003c\/td\u003e\n    \u003ctd\u003eNo extracapsular invasion\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eT3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u0026gt;4 cm\u003c\/td\u003e\n    \u003ctd\u003eOR minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eT4a\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eAny size\u003c\/td\u003e\n    \u003ctd\u003eBeyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eT4b\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eAny size\u003c\/td\u003e\n    \u003ctd\u003eInvades prevertebral fascia, or encases carotid artery or mediastinal vessels\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eNote: Patients with differentiated thyroid cancer \u003cstrong\u003eyounger than 45 years\u003c\/strong\u003e can only be staged as stage I or II (stage II means metastatic disease). For patients 45 and older with DTC, and for MTC patients of any age, distant metastasis (M1) means stage IVc. All anaplastic carcinomas are by definition T4a or T4b, so all are stage IV.\u003c\/p\u003e\n\n\u003ch3\u003eHow Accurate Are CT and MRI for Detecting Invasion?\u003c\/h3\u003e\n\n\u003cp\u003eMRI and CT have \u003cstrong\u003esimilar accuracy\u003c\/strong\u003e for predicting invasion of the esophagus, trachea\/larynx, and recurrent laryngeal nerve. The key numbers from several retrospective studies:\u003c\/p\u003e\n\n\u003ctable border=\"1\" cellpadding=\"8\" cellspacing=\"0\"\u003e\n  \u003ctr\u003e\n    \u003cth\u003eStructure\u003c\/th\u003e\n    \u003cth\u003eCT sensitivity \/ specificity \/ accuracy\u003c\/th\u003e\n    \u003cth\u003eCT criteria\u003c\/th\u003e\n    \u003cth\u003eMRI sensitivity \/ specificity \/ accuracy\u003c\/th\u003e\n    \u003cth\u003eMRI criteria\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eTrachea\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e59% \/ 91% \/ 83%\u003c\/td\u003e\n    \u003ctd\u003eOne of: ≥180° circumferential contact, lumen deformity, mucosal abnormality\u003c\/td\u003e\n    \u003ctd\u003e100% \/ 84% \/ 90%\u003c\/td\u003e\n    \u003ctd\u003eOne of: ≥180° circumferential contact, soft tissue signal in cartilage, intraluminal mass\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eEsophagus\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e29% \/ 96% \/ 91%\u003c\/td\u003e\n    \u003ctd\u003e≥180° circumferential contact OR abnormal wall or lumen\u003c\/td\u003e\n    \u003ctd\u003e82% \/ 94% \/ 91%\u003c\/td\u003e\n    \u003ctd\u003eOuter layer invasion\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRecurrent laryngeal nerve\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e78% \/ 90% \/ (not stated)\u003c\/td\u003e\n    \u003ctd\u003e2 of: effaced fatty tissue in tracheoesophageal groove, vocal cord dysfunction\u003c\/td\u003e\n    \u003ctd\u003e94% \/ 82% \/ (not stated)\u003c\/td\u003e\n    \u003ctd\u003eEffaced fatty tissue in tracheoesophageal groove on at least one axial image\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe main sign for tracheal and esophageal invasion on both MRI and CT is a \u003cstrong\u003emass contacting 180° or more of the organ's circumference\u003c\/strong\u003e. Other findings suggesting tracheal invasion include deformity of the lumen, focal mucosal irregularity or thickening, and an intraluminal mass. The esophagus is harder to evaluate than the trachea because it doesn't naturally contain air to outline its interior. On MRI, the most suspicious finding for esophageal invasion is a \u003cstrong\u003efocal T2 signal in the outer layer of the esophageal wall\u003c\/strong\u003e. On CT, loss of the normal esophageal wall and lumen is the key clue.\u003c\/p\u003e\n\n\u003cp\u003eInvasion of the \u003cstrong\u003erecurrent laryngeal nerve (RLN)\u003c\/strong\u003e — the nerve controlling the vocal cords — can be predicted by effaced fatty tissue in the tracheoesophageal groove where the nerve travels. Other imaging signs include vocal cord dysfunction and \u003cstrong\u003e25% or more of the primary tumor's circumference abutting the capsule at the posterior portion of the thyroid\u003c\/strong\u003e (the \"sign of posterior extracapsular invasion\").\u003c\/p\u003e\n\n\u003cp\u003eVascular and prevertebral space invasion are designated \u003cstrong\u003eT4b disease\u003c\/strong\u003e and generally \u003cstrong\u003epreclude curative surgery\u003c\/strong\u003e. Dr. Seo and colleagues found that \u003cstrong\u003econtact of the tumor with 180° or more of the vessel circumference\u003c\/strong\u003e was a highly specific sign for invasion of the common carotid artery and internal jugular vein on CT. However, a different study of head and neck tumors found this sign had only \u003cstrong\u003e50% accuracy\u003c\/strong\u003e for arterial invasion due to many false negatives. That study found more accurate CT signs to be \u003cstrong\u003earterial compression or deformation, or fat\/fascial plane deletion — with 84% accuracy\u003c\/strong\u003e. Increasing the circumferential encasement threshold to \u003cstrong\u003e270°\u003c\/strong\u003e improves specificity further; on MRI this sign had \u003cstrong\u003e100% sensitivity and 88% specificity\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eFor prevertebral muscle invasion, MRI can exclude involvement if the retropharyngeal fat is preserved. However, confirming invasion using findings like muscle T2 hyperintensity, enhancement, or contour abnormality is less reliable, with accuracy of only \u003cstrong\u003e60%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eCT and MRI also play a secondary but valuable role in detecting \u003cstrong\u003eanomalous anatomy\u003c\/strong\u003e that could complicate surgery. One example is the \u003cstrong\u003enon-recurrent inferior laryngeal nerve (NRILN)\u003c\/strong\u003e, a variant where the nerve branches directly from the vagus nerve and enters the larynx instead of looping under the right subclavian artery. Radiologists can suspect a right NRILN when they see an \u003cstrong\u003eaberrant right subclavian artery\u003c\/strong\u003e — a warning that helps surgeons avoid injuring the nerve.\u003c\/p\u003e\n\n\u003ch2 id=\"recurrence\"\u003eEvaluating for Recurrence After Treatment\u003c\/h2\u003e\n\n\u003cp\u003eAfter treatment for differentiated thyroid cancer, \u003cstrong\u003eserum thyroglobulin level\u003c\/strong\u003e is used as a tumor marker. When thyroglobulin rises, the standard next steps are a neck ultrasound and a whole-body iodine scan (using 131I or 123I).\u003c\/p\u003e\n\n\u003cp\u003eHere's the challenge: the whole-body iodine scan is \u003cstrong\u003enegative in 50–80% of patients\u003c\/strong\u003e who actually have recurrent or persistent disease. This situation represents progression to \u003cstrong\u003ededifferentiated thyroid cancer\u003c\/strong\u003e — the tumor cells have lost their ability to take up iodine, making them invisible on iodine scanning but potentially visible on other imaging.\u003c\/p\u003e\n\n\u003cp\u003eIn these cases, \u003cstrong\u003eMRI or PET\/CT\u003c\/strong\u003e can help locate the recurrence. MRI has two advantages:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eIt can be performed safely without interfering with future iodine-based treatments, since MRI contrast is not iodinated\u003c\/li\u003e\n  \u003cli\u003eIt can detect nodal disease with high protein content from colloid, thyroglobulin, and blood products\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe role of retropharyngeal nodal evaluation becomes even more critical after lateral and central neck dissections have been performed, as anatomy is altered and normal drainage pathways have been disrupted.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePET\/CT has 81–82% sensitivity and 64–89% specificity\u003c\/strong\u003e for detecting recurrent tumor in patients with elevated thyroglobulin and a negative whole-body iodine scan. As tumors dedifferentiate, their tendency to take up FDG increases — but intense FDG uptake, while correlated with more aggressive disease, doesn't always mean a worse prognosis. A notable pitfall is that most thyroid nodal metastases are small and may fall below the resolution limits of PET\/CT, producing false negatives.\u003c\/p\u003e\n\n\u003cp\u003eBeyond regional lymph nodes, PET\/CT can also detect \u003cstrong\u003eunrecognized distant metastases in the lungs and bones\u003c\/strong\u003e — information that can change treatment from a curative approach to a palliative one if disease is too extensive.\u003c\/p\u003e\n\n\u003cp\u003eFor medullary thyroid carcinoma, the tumor markers are \u003cstrong\u003eserum calcitonin and carcinoembryonic antigen (CEA)\u003c\/strong\u003e. FDG-PET uptake can be helpful when positive, but FDG avidity in MTC is variable, making negative scans difficult to interpret.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eSeveral practical messages emerge from this review:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, an incidental thyroid nodule is common and usually benign.\u003c\/strong\u003e The malignancy rate is only 0–9%, and even when cancer is present, survival rates for the common types exceed 85–95% at 10 years. The new 3-tiered reporting system helps avoid unnecessary procedures while still catching dangerous cancers.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, if you've been scheduled for a contrast CT and have known thyroid cancer, ask about timing.\u003c\/strong\u003e The iodine in CT contrast can block your thyroid's iodine uptake for 6–8 weeks, potentially delaying radioiodine treatment by 2–6 months. MRI with gadolinium contrast does not have this problem.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, if you present with a neck mass that turns out to be a cystic lymph node, thyroid cancer must be considered\u003c\/strong\u003e — even in young adults, even if the thyroid looks normal on imaging. Surgical specimens frequently reveal small multifocal cancers that were invisible on scans.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFourth, CT and MRI are powerful tools for surgical planning.\u003c\/strong\u003e They determine whether cancer has invaded the trachea, esophagus, nerve, blood vessels, or prevertebral space — information that guides whether surgery is feasible and which surgical team should be involved.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFifth, after treatment, a rising thyroglobulin level with a negative iodine scan requires further evaluation\u003c\/strong\u003e with MRI or PET\/CT. A negative iodine scan does \u003cem\u003enot\u003c\/em\u003e mean you're cancer-free.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eThis is a review article, meaning the authors analyzed and summarized existing research rather than conducting a new clinical trial. Several limitations of the underlying research should be acknowledged:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMost accuracy data come from retrospective studies\u003c\/strong\u003e, which are more prone to bias than prospective trials.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCT and MRI cannot reliably determine tumor histology\u003c\/strong\u003e (cell type) or diagnose multifocal disease — small cancers, diffuse growth patterns, and multifocal tumors are frequently invisible on cross-sectional imaging.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSize criteria are imperfect.\u003c\/strong\u003e Up to 61% of nodal metastases are smaller than 10 mm, meaning normal-sized lymph nodes can still harbor cancer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVascular invasion assessment is challenging.\u003c\/strong\u003e Depending on the criteria used, accuracy for arterial invasion ranged from as low as 50% to 84–88% on MRI with 270° encasement threshold.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe 3-tiered reporting system\u003c\/strong\u003e was validated in a single institution's cohort of 133 nodules plus a national database; wider validation in diverse practice settings would strengthen confidence in its generalizability.\u003c\/li\u003e\n  \u003cli\u003eThe review was published in 2013; imaging technology and guidelines have continued to evolve since that time.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this research, here are actionable steps patients can take:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about the contrast agent.\u003c\/strong\u003e If you have known or suspected thyroid cancer and are scheduled for a CT scan, discuss with your doctor whether iodinated contrast is necessary or whether MRI (gadolinium-based contrast) could be used instead — particularly if radioiodine therapy is planned in the near future.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't panic about an incidental nodule.\u003c\/strong\u003e Most incidental thyroid nodules are benign, and even malignant ones are often low-risk. Ask your radiologist or doctor which risk category your nodule falls into based on the 3-tiered system described above.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFollow through on recommended ultrasound.\u003c\/strong\u003e If your report suggests ultrasound for further characterization, schedule it. Ultrasound provides the most detailed information about nodule features that predict cancer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have a cystic neck mass\u003c\/strong\u003e — especially if you're a young adult — insist that thyroid cancer be ruled out before assuming it's a congenital cyst.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor patients with known thyroid cancer:\u003c\/strong\u003e understand that CT and MRI play a complementary role to ultrasound. They help detect invasion and nodal spread in areas ultrasound can't fully evaluate, such as the mediastinum (area behind the breastbone) and retropharyngeal space.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAfter treatment, keep up with thyroglobulin monitoring.\u003c\/strong\u003e If your thyroglobulin is rising but your iodine scan is negative, talk to your specialist about MRI or PET\/CT to locate potential recurrence or metastasis.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThese steps reflect the central message of this review: thoughtful, informed use of CT and MRI can spare patients unnecessary procedures while catching the cancers that truly matter.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is an incidental thyroid nodule found on a CT or MRI scan?\u003c\/h3\u003e\n\u003cp\u003eAn incidental thyroid nodule is a growth in your thyroid found on a scan done for another reason. These are common, appearing in up to 1 in 6 neck CT scans. Most are benign, with cancer found in only 0% to 9% of cases, so finding one does not mean you have cancer.\u003c\/p\u003e\n\u003ch3\u003eShould I worry if a thyroid nodule is found by chance on a CT scan?\u003c\/h3\u003e\n\u003cp\u003eMost incidental thyroid nodules are benign, and even cancers are often slow-growing with excellent survival, exceeding 95% at 10 years for the common type. Your doctor may use a risk system based on size, your age, and scan features to decide if ultrasound or biopsy is needed, avoiding unnecessary tests.\u003c\/p\u003e\n\u003ch3\u003eWhy might my doctor choose MRI instead of a contrast CT scan for thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eIodinated CT contrast can block your thyroid's iodine uptake for 6 to 8 weeks, delaying radioiodine scans or treatment by 2 to 6 months. MRI contrast, called gadolinium, does not interfere with iodine uptake, so MRI is often a valuable alternative when iodine-based treatment is planned soon.\u003c\/p\u003e\n\u003ch3\u003eI have a cystic neck mass. Could it be thyroid cancer even if my thyroid looks normal?\u003c\/h3\u003e\n\u003cp\u003eYes. Cystic neck masses in young adults should not be dismissed as harmless congenital cysts. In one case, a 19-year-old woman's simple-looking cyst was actually a lymph node metastasis from a 1-cm papillary thyroid carcinoma. Sometimes small or multifocal thyroid cancers are invisible on CT, MRI, or even ultrasound.\u003c\/p\u003e\n\u003ch3\u003eAfter thyroid cancer treatment, my thyroglobulin is rising but my iodine scan is negative. What does that mean?\u003c\/h3\u003e\n\u003cp\u003eA negative whole-body iodine scan occurs in 50% to 80% of patients who actually have recurrent or persistent disease. This can mean the cancer has lost its ability to take up iodine. In this situation, MRI or PET\/CT can help locate the recurrence, so a negative iodine scan does not mean you are cancer-free.\u003c\/p\u003e\n\u003ch3\u003eHow accurate are CT and MRI at detecting if thyroid cancer has spread to nearby structures?\u003c\/h3\u003e\n\u003cp\u003eCT and MRI have similar accuracy for predicting invasion of the esophagus, trachea\/larynx, and recurrent laryngeal nerve. For example, MRI sensitivity for tracheal invasion was 100% and CT was 59% in one study, while specificity was 84% and 91%, respectively. Both use a 180-degree contact sign as a key indicator.\u003c\/p\u003e\n\u003ch3\u003eWhat is the chance an enlarged lymph node is thyroid cancer if my thyroid looks normal on scans?\u003c\/h3\u003e\n\u003cp\u003eSometimes an enlarged lymph node is the first sign of thyroid cancer. In this situation, any thyroid nodule seen on CT or MRI should be treated as suspicious and checked with ultrasound. One patient had a normal thyroid on CT and ultrasound, yet surgery found multifocal papillary cancers from 0.1 cm to 1.4 cm.\u003c\/p\u003e\n\u003ch3\u003eMy thyroid nodule was found on a CT scan. Should I get a second opinion on the imaging before deciding on biopsy or surgery?\u003c\/h3\u003e\n\u003cp\u003eA second opinion can help you interpret incidental thyroid nodule findings. CT and MRI cannot reliably determine if a nodule is cancerous or detect multifocal disease. Most incidental nodules are benign; malignancy rates are only 0–9%. A second opinion may clarify whether ultrasound-guided biopsy is needed or whether observation is safe. If surgery is planned for invasive disease, expert imaging review can confirm whether the trachea, esophagus, or nerves are involved, affecting surgical approach. Also, MRI may be preferable to contrast CT if radioiodine treatment is anticipated. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Imaging of thyroid carcinoma with CT and MRI 2013\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Jenny K. Hoang, Barton F. Branstetter IV, Andreia R. Gafton, Wai K. Lee, Christine M. Glastonbury\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Cancer Imaging (2013) 13(1), 128–139\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1102\/1470-7330.2013.0013\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication date:\u003c\/strong\u003e Accepted for publication 18 January 2013\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eNote:\u003c\/em\u003e This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace professional medical advice. Always discuss imaging findings and treatment options with your healthcare team.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576654348444,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/es\/products\/understanding-thyroid-cancer-imaging-a-patients-guide-to-ct-and-mri-scans","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}